This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Deschloroketamine: Difference between revisions
>Tracer |
>Nibbana updated antibacterial information |
||
| Line 5: | Line 5: | ||
'''2'-Oxo-PCM''' (also known as '''deschloroketamine''', '''O-PCM''', '''DXE''', and '''DCK''') is a lesser-known novel [[psychoactive class::dissociative]] substance of the [[chemical class::arylcyclohexylamine]] class that produces [[dissociative]], [[pain relief|anesthetic]] and [[hallucinogenic]] effects when [[Routes of administration|administered]].<ref name="name">Synthesis and in vitro evaluation of (18)F-labelled S-fluoroalkyl diarylguanidines: Novel high-affinity NMDA receptor antagonists for imaging with PET (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/20138515</ref><ref name="patent">Patent US 3254124 - Aminoketones and methods for their production | http://www.google.com/patents/US3254124</ref> | '''2'-Oxo-PCM''' (also known as '''deschloroketamine''', '''O-PCM''', '''DXE''', and '''DCK''') is a lesser-known novel [[psychoactive class::dissociative]] substance of the [[chemical class::arylcyclohexylamine]] class that produces [[dissociative]], [[pain relief|anesthetic]] and [[hallucinogenic]] effects when [[Routes of administration|administered]].<ref name="name">Synthesis and in vitro evaluation of (18)F-labelled S-fluoroalkyl diarylguanidines: Novel high-affinity NMDA receptor antagonists for imaging with PET (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/20138515</ref><ref name="patent">Patent US 3254124 - Aminoketones and methods for their production | http://www.google.com/patents/US3254124</ref> | ||
Early discussion over DCK has revolved around speculation over claims of antibacterial or immunosuppressant properties. If this speculation is valid, it is possible that its prolonged use could potentially pose a serious threat to one's health and immune system, which is why misuse of this substance is highly discouraged | Early discussion over DCK has revolved around speculation over claims of antibacterial or immunosuppressant properties. If this speculation is valid, it is possible that its prolonged use could potentially pose a serious threat to one's health and immune system, which is why misuse of this substance is highly discouraged.<ref name="DCKAntibacterial">Preiss, D., & Tartar, A. (1998). U.S. Patent No. US5811464. Washington, DC: U.S. Patent and Trademark Office. | https://www.google.com/patents/US5811464</ref> Ketamine has been found to have similar properties.<ref>https://pubmed.ncbi.nlm.nih.gov/18521797/</ref> | ||
DCK has recently become easily accessible through online [[research chemical]] vendors<ref name="name" /> where it is being sold as a [[designer drug]].<ref>Characterization of the [[designer drug]] deschloroketamine (2-methylamino-2-phenylcyclohexanone) by gas chromatography/mass spectrometry, liquid chromatography/high-resolution mass spectrometry, multistage mass spectrometry, and nuclear magnetic resonance (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/26661982</ref><ref>Alert: descloroketamina sold as ketamine in Barcelona | http://energycontrol.org/analisis-de-sustancias/resultados/alertas/560-alerta-descloroketamina-vendida-como-ketamina-en-barcelona.html</ref><ref>The unknown effects of drought ketamine | http://www.vice.com/es/read/los-efectos-desconocidos-de-la-sequia-de-ketamina-719</ref> | DCK has recently become easily accessible through online [[research chemical]] vendors<ref name="name" /> where it is being sold as a [[designer drug]].<ref>Characterization of the [[designer drug]] deschloroketamine (2-methylamino-2-phenylcyclohexanone) by gas chromatography/mass spectrometry, liquid chromatography/high-resolution mass spectrometry, multistage mass spectrometry, and nuclear magnetic resonance (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/26661982</ref><ref>Alert: descloroketamina sold as ketamine in Barcelona | http://energycontrol.org/analisis-de-sustancias/resultados/alertas/560-alerta-descloroketamina-vendida-como-ketamina-en-barcelona.html</ref><ref>The unknown effects of drought ketamine | http://www.vice.com/es/read/los-efectos-desconocidos-de-la-sequia-de-ketamina-719</ref> | ||
| Line 118: | Line 118: | ||
{{#ask: [[Category:Deschloroketamine]][[Category:Experience]]|format=ul|Columns=1}} | {{#ask: [[Category:Deschloroketamine]][[Category:Experience]]|format=ul|Columns=1}} | ||
Additional experience reports can be found here: | Additional experience reports can be found here: | ||
* [https://erowid.org/experiences/subs/exp_Deschloroketamine.shtml Erowid Experience Vaults: Deschloroketamine] | |||
*[https://erowid.org/experiences/subs/exp_Deschloroketamine.shtml Erowid Experience Vaults: Deschloroketamine] | |||
==Toxicity and harm potential== | ==Toxicity and harm potential== | ||
{{ | {{Further|Research chemicals#Toxicity and harm potential}} | ||
The toxicity and long-term health effects of recreational DCK use do not seem to have been studied in any scientific context and the [[Toxicity::exact toxic dosage is unknown]]. This is because DCK has very little history of human usage. Anecdotal evidence from people who have tried DCK within the community suggests that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption. | The toxicity and long-term health effects of recreational DCK use do not seem to have been studied in any scientific context and the [[Toxicity::exact toxic dosage is unknown]]. This is because DCK has very little history of human usage. Anecdotal evidence from people who have tried DCK within the community suggests that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption. | ||
| Line 135: | Line 136: | ||
In terms of its long-term health effects when used repeatedly and with excess for extended periods of time, DCK seems to exhibit almost identical bladder and urinary tract problems to those found within [[ketamine]] but to a lesser extent. This is suspected to be because DCK is more potent than ketamine, meaning that less of the drug needs to be consumed to produce analogous effects. Symptoms of ketamine-induced cystitis can become extremely serious and include: | In terms of its long-term health effects when used repeatedly and with excess for extended periods of time, DCK seems to exhibit almost identical bladder and urinary tract problems to those found within [[ketamine]] but to a lesser extent. This is suspected to be because DCK is more potent than ketamine, meaning that less of the drug needs to be consumed to produce analogous effects. Symptoms of ketamine-induced cystitis can become extremely serious and include: | ||
*'''Urinary frequency''' - Urinary frequency is the need to empty the bladder every few minutes. | *'''Urinary frequency''' - Urinary frequency is the need to empty the bladder every few minutes. | ||
*'''Urinary urgency''' - This can be described as a sudden, compelling need to urinate. | *'''Urinary urgency''' - This can be described as a sudden, compelling need to urinate. | ||
*'''Urinary pressure''' - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination. | *'''Urinary pressure''' - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination. | ||
| Line 150: | Line 151: | ||
==Legal status== | ==Legal status== | ||
{{LegalStub}} | {{LegalStub}} | ||
*'''Latvia:''' Deschloroketamine is illegal in Latvia.<ref>Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem | http://www.vm.gov.lv/images/userfiles/metodiskas_vadlinijas_080914.doc</ref> | *'''Latvia:''' Deschloroketamine is illegal in Latvia.<ref>Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem | http://www.vm.gov.lv/images/userfiles/metodiskas_vadlinijas_080914.doc</ref> | ||
*'''Germany:''' Deschloroketamine is not a controlled substance under the BtMG.<ref>http://www.gesetze-im-internet.de/btmg_1981/anlage_i.html</ref> It is legal, as long as it is not sold for human consumption, according to §2 AMG.<ref>https://www.gesetze-im-internet.de/amg_1976/__2.html</ref> | *'''Germany:''' Deschloroketamine is not a controlled substance under the BtMG.<ref>http://www.gesetze-im-internet.de/btmg_1981/anlage_i.html</ref> It is legal, as long as it is not sold for human consumption, according to §2 AMG.<ref>https://www.gesetze-im-internet.de/amg_1976/__2.html</ref> | ||
| Line 156: | Line 158: | ||
==See also== | ==See also== | ||
*[[Responsible use]] | *[[Responsible use]] | ||
*[[Designer drug]] | *[[Designer drug]] | ||
| Line 164: | Line 167: | ||
==External links== | ==External links== | ||
*[https://en.wikipedia.org/wiki/Deschloroketamine Deschloroketamine (Wikipedia)] | *[https://en.wikipedia.org/wiki/Deschloroketamine Deschloroketamine (Wikipedia)] | ||
*[https://isomerdesign.com/PiHKAL/explore.php?id=985 Deschloroketamine (Isomer Design)] | *[https://isomerdesign.com/PiHKAL/explore.php?id=985 Deschloroketamine (Isomer Design)] | ||
===Discussion=== | ===Discussion=== | ||
*[http://www.bluelight.org/vb/threads/766127-The-Small-amp-Handy-Deschloroketamine-Thread The Big & Dandy Deschloroketamine Thread (Bluelight)] | *[http://www.bluelight.org/vb/threads/766127-The-Small-amp-Handy-Deschloroketamine-Thread The Big & Dandy Deschloroketamine Thread (Bluelight)] | ||
==Literature== | ==Literature== | ||
* Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620 | |||
*Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620 | |||
==References== | ==References== | ||
<references /> | <references /> | ||
[[Category:Substance]] | |||
[[Category:Psychoactive substance]] | |||
[[Category:Hallucinogen]] | |||
[[Category:Dissociative]] | |||
[[Category:Arylcyclohexylamine]] | [[Category:Arylcyclohexylamine]] | ||
[[Category:Research chemical]] | [[Category:Research chemical]] | ||